Insight Molecular Diagnostics (IMDX) Current Deferred Revenue (2018)
Insight Molecular Diagnostics (IMDX) posted Current Deferred Revenue of $738000.0 for Q2 2018.
Insight Molecular Diagnostics (IMDX) Current Deferred Revenue (2018) Analysis & Trends
Insight Molecular Diagnostics (IMDX) has 1 years of Current Deferred Revenue data on file, last reported at $738000.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Waters | 31,055.11 Bn | 31,054.65 Bn | 1.11 Bn |
| 2 | Thermo Fisher Scientific | 191.02 Bn | 187.77 Bn | 7.74 Bn |
| 3 | Danaher | 137.16 Bn | 131.47 Bn | 3.59 Bn |
| 4 | Idexx Laboratories | 42.82 Bn | 42.62 Bn | 722.74 Mn |
| 5 | Natera | 39.09 Bn | 37.99 Bn | 696.04 Mn |
| 6 | Agilent Technologies | 37.61 Bn | 35.81 Bn | 990.00 Mn |
| 7 | Iqvia Holdings | 34.23 Bn | 32.25 Bn | 1.36 Bn |
| 8 | Illumina | 28.14 Bn | 26.98 Bn | 721.00 Mn |
| 9 | Mettler Toledo International | 26.40 Bn | 26.33 Bn | 555.82 Mn |
| 10 | Insight Molecular Diagnostics | 196.41 Mn | 167.48 Mn | 15,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 738,000.00 |